Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries.

ABSTRACT:

Objective

Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country.

Methods

Retrospective quantitative analysis using insulin glargine pricing data, both of the originator product and its biosimilars. Segmented regression analysis using a dual-model approach: pooled and country-specific.

Setting

28 European countries using data from the European Medicine Price Database for the period 2013-2023.

Main outcome measures

Price variations between countries were analysed to assess trends and correlations before and after biosimilar market entry.

Results

In the 28 countries studied, cost of insulin glargine underwent a median 21.6% decrease overall in the

SUBMITTER: Morolla D 

PROVIDER: S-EPMC11795371 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature